Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of Tivanisiran to Treat Dry Eye
NCT05310422Phase 3Completed
- Sponsor
- Sylentis
- Start
- Mar 2022
- Primary completion
- Oct 2023
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 3 trial of tivanisiran in dry eye disease (DED), sponsored by Sylentis. Started Mar 2022; status: completed.
02
Drugs
tivanisiran
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05310422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05310422.